Addressing viral genomic variability towards developing a Cas13b-based therapy
The findings show that a “one size fits all” approach for PspCas13b-mediated treatment of HBV is unlikely to be effective, but the impact of sequence variability on PspCas13b efficacy can be readily addressed through appropriate design of crRNAs.